Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged misleading statements regarding its drug candidates, potentially impacting investors who purchased securities during the specified period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to purchasers of Biohaven securities between March 24, 2023, and May 14, 2025 [1]. - Allegations include overstated regulatory prospects for the drug troriluzole and its efficacy for treating spinocerebellar ataxia and bipolar disorder, which may have negatively affected Biohaven's business and financial condition [5]. Group 2: Investor Information - Investors who purchased Biohaven securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. on behalf of shareholders who purchased securities between March 24, 2023, and May 14, 2025, due to alleged misleading statements regarding the company's drug candidates [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven made false and misleading statements about the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which were overstated [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering over $438 million for investors in 2019 alone [4]. - Investors can choose to remain absent from the class or select their own counsel, as no class has been certified yet [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's drug candidates and their regulatory prospects [3][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [3][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false or misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [5]. - It is claimed that the overstated regulatory prospects and clinical data could significantly negatively impact Biohaven's business and financial condition once revealed [5]. Group 3: Stock Price Impact - Following a press release on May 14, 2025, regarding the extension of the PDUFA date for troriluzole, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged violations of securities laws, specifically related to misleading statements about its drug candidates [1][4]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Biohaven made false and misleading statements regarding the regulatory prospects of its drug candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder [4]. - The class period for the lawsuit is defined as March 24, 2023, to May 14, 2025, during which investors are encouraged to participate if they suffered losses [2]. Group 2: Investor Information - Investors who purchased Biohaven's securities during the class period are urged to contact the Schall Law Firm before September 12, 2025, to discuss their rights [2][3]. - The class has not yet been certified, meaning that until certification occurs, affected investors are not represented by an attorney [3].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations - The lawsuit claims that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole as a treatment for SCA [2]. - It is also alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The revelations from the lawsuit are expected to have a significant negative impact on Biohaven's business and financial condition [2]. Group 3: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and operations [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased Biohaven securities between March 24, 2023, and May 14, 2025, inclusive [2]. Case Details - The Complaint alleges that Defendants overstated the regulatory prospects of troriluzole as a treatment for SCA and the efficacy of BHV-7000 for bipolar disorder, which could significantly negatively impact Biohaven's business and financial condition [3]. Next Steps - Investors who suffered losses in Biohaven have until September 12, 2025, to request to be appointed as lead plaintiff in the case [4]. Cost Structure - The law firm represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Points - A shareholder class action lawsuit has been filed against Biohaven Ltd. alleging materially false and misleading statements regarding the company's business and operations [1] - The lawsuit specifically claims that the regulatory prospects of troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder were overstated [1] - The lawsuit suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [1] Legal Context - Shareholders who purchased Biohaven shares between March 24, 2023, and May 14, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is September 12, 2025 [3] - Holzer & Holzer, LLC is representing shareholders and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - A securities class action lawsuit has been filed against Biohaven Ltd. for allegedly making false and misleading statements regarding its drug candidates, which has negatively impacted its stock price and financial condition [1][2]. Group 1: Legal Action - A class action lawsuit has been initiated in the U.S. District Court for the District of Connecticut on behalf of individuals or entities that acquired Biohaven securities between March 24, 2023, and May 14, 2025 [1]. - The lawsuit claims that Biohaven overstated the regulatory prospects of its drug troriluzole and the efficacy of BHV-7000 for bipolar disorder, which were not disclosed accurately [2]. Group 2: Stock Price Impact - Following the FDA's rejection of the troriluzole NDA on July 27, 2023, Biohaven's stock price dropped by $5.38, or 22.61%, closing at $18.42 per share [3]. - On March 3, 2025, after disclosing disappointing results for BHV-7000, Biohaven's stock fell by $5.12, or 13.77%, closing at $32.06 per share [5]. Group 3: Company Developments - Biohaven resubmitted the troriluzole NDA to the FDA on December 16, 2024, citing additional positive efficacy data [4]. - The company reported that a late-stage study of BHV-7000 did not meet its primary outcome measure, raising concerns about its clinical prospects [5].

Pipeline Highlights - Troriluzole's NDA is under priority review for Spinocerebellar Ataxia (SCA), with a PDUFA date in 2H 2025[14, 118, 434], and if approved, commercial launch is expected in 2H 2025[434] The company estimates there are approximately 15,000 SCA patients in the US[441, 502] and troriluzole reduced SCA disease progression by 50% to 70% in RWE study[463, 468, 473, 501] - Kv7 activator BHV-7000 expects topline results for Major Depressive Disorder (MDD) in 2H 2025[14, 158, 161, 216] and Phase 3 focal epilepsy study topline results in 1H 2026[14, 158, 163] - Taldefgrobep Alfa has a planned FDA interaction in 1H 2025 regarding the Spinal Muscular Atrophy (SMA) registrational path[12, 396] and a Phase 2 obesity study is planned for 2H 2025[12, 342] - IgG Degrader BHV-1300 is expected to initiate a pivotal Graves' disease study in 2H 2025[10, 85, 90, 91, 40, 42] and Myasthenia Gravis study in 2026[10, 42, 93, 94] - Gd-IgA1 Degrader BHV-1400 completed Phase 1 and is expected to initiate a pivotal IgA Nephropathy (IgAN) study in 2026[10, 42, 47, 64] - β1AR AAb Degrader BHV-1600 expects to complete Phase 1 in 2H 2025 and initiate a pivotal Peripartum Cardiomyopathy (PPCM) study in 2026[10, 42, 114, 119] Immunology & Inflammation Platform - The company's MoDE and TRAP degraders have been dosed in 166 individuals[35] - BHV-1300 achieved median maximal reductions in total IgG of 83% by day 18[70, 73] - A single subcutaneous dose of BHV-1400 delivered rapid, selective, deep, and sustained reductions in Gd-IgA1 of up to 81% without suppression of healthy immunoglobulins[55] Oncology Platform - Trop2 ADC BHV-1510 is in Phase 1, with interim data expected in 2H 2025[12, 524, 581] Preliminary data shows tumor reduction in first 6 patients treated with BHV-1510 + cemiplimab combination[543, 546] - FGFR3 ADC BHV-1530 initiated Phase 1 in April 2025[12, 524, 576, 581] Financial Update - The company has approximately $518 million in cash[578, 579] - Potential royalties from Pfizer could reach up to $400 million per year, based on low- to mid-teens % of annual US net sales of rimegepant and zavegepant exceeding $525 billion[577, 578]

Core Insights - Bexorg, Inc. has announced a multi-program research collaboration with Biohaven Ltd. to advance next-generation therapies for central nervous system (CNS) disorders [1] - Bexorg's whole-brain discovery platform is unique in its ability to restore metabolic and molecular activity in isolated human and pig brains, enabling high-resolution insights into neurodegeneration [2][5] - The collaboration aims to provide insights into pharmacokinetics, pharmacodynamics, and mechanisms of action for Biohaven's therapeutics, potentially identifying novel biomarkers for clinical trials [3] Company Overview - Bexorg is a techbio company focused on CNS drug discovery, utilizing a proprietary platform called BrainEx to generate clinically predictive data from postmortem human brains [5][6] - Biohaven is a biopharmaceutical company developing treatments in areas such as immunology, neuroscience, and oncology, with a diverse portfolio including therapies for epilepsy, mood disorders, and cancer [4] Technological Advancements - Bexorg's whole-brain perfusion technology allows for the extraction of detailed transcriptomic, proteomic, and metabolic data, which is essential for machine learning and AI-driven drug discovery [2][6] - The platform addresses the limitations of traditional preclinical models by providing a more accurate representation of human brain structure and function, thus enhancing CNS drug development [3]